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A B S T R A C T
Despite the popularity of orally fast disintegrating tablets (FDTs), their formulation can sometimes be
challenging, producing tablets with either poor mechanical properties or high disintegration times. The
aim of this research was to enhance the properties of FDTs produced by direct compression to have both
sufﬁcient hardness to withstand manual handling, and rapid disintegration time. General multilevel
factorial design was applied to optimise and evaluate main and interaction effects of independent
variables (i) disintegrant concentration, (ii) % ﬁller (Disintequick MCC-25) to mannitol on the responses
hardness, tensile strength and disintegration time. In this experiment mannitol was used as a diluent,
Disintequick MCC-25 (to best of our knowledge there is no publication available yet for its use with FDTs)
was termed in this study as a ﬁller and croscaremellose sodium was used as the superdisintegrant. Seven
formulations were prepared following a progressive two-stage approach. Each stage involved the change
in the ratio of excipients (Mannitol:Filler) (1:0), (1:0.25), (1:0.50), (1:1), (0.50:1), (0.25:1), (0:1) w/w and
concentration of superdisintegrant (1%, 3%, 5%, 7%, 10% w/w). All FDTs were tested for different
parameters such as diameter, hardness, tensile strength, thickness, friability and disintegration time. The
results of multiple linear regression analysis show a good degree of correlation between experimental
(R2:0.84, 0.94, 0.91) and predicted response (R2:0.83, 0.96, 0.95) for hardness, tensile strength and
disintegration time respectively. The optimum formulations (regarding disintegration time with
acceptable hardness and friability properties) consisted of: (i) 5% w/w disintegrant and 20% w/w ﬁller to
mannitol, showing a disintegration time of 30 s, a hardness of 66.6 N (6.8 kg/cm2) and friability of 2.2%;
(ii) 7% or 10% w/w disintegrant with 33.33% w/w ﬁller to mannitol, showing disintegration time of 84 s
(for 7% disintegrant) and 107 s (for 10% disintegrant), hardness of 73.86 N (for 7% disintegrant) and
72.68 N (for 10% disintegrant) and friability of 1.44 (for 7% disintegrant) and 1.15% (for 10% disintegrant).
ã 2016 Elsevier B.V. All rights reserved.
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Orally fast disintegrating tablets (FDTs), also referred to as fast
melt, quick melt, oro-disperse, rapidly disintegrating, among
others (Nagar et al., 2011; Rao et al., 2012; Deshmukh, 2012) are
according to the US Food and Drug Administration (FDA) a “solid
dosage form containing medicinal substances which disintegrate
rapidly within a matter of seconds, when placed upon the tongue”
(FDA, 2008). The European Pharmacopeia describes them as
“uncoated tablets intended to be placed in the mouth where they* Corresponding author at: University of Sunderland, Department of Pharmacy,
Health and Well-being, Sunderland SR1 3SD, UK.
E-mail address: amal.elkordy@sunderland.ac.uk (A.A. Elkordy).
http://dx.doi.org/10.1016/j.ijpharm.2016.01.065
0378-5173/ã 2016 Elsevier B.V. All rights reserved.disperse rapidly before being swallowed” it is also stated that the
disintegration time is within 3 min (British Pharmacopoeia,
2013).
FDTs provide patients with an effective alternative for taking
their medication. They compensate many pharmaceutical and
patient’s needs (Abay and Ugurlu, 2015), particularly paediatric,
geriatric and bedridden patients, patients with dysphagia, or even
for those who are travelling and have little or no access to water
(Nagar et al., 2011; Arora and Sethi, 2013; Abay and Ugurlu, 2015;
Sharma et al., 2012). FDTs disperse or dissolve in the saliva, this
leads to pre-gastric drug absorption of the tablets. As a result, FDTs
have greater bioavailability than that observed from conventional
tablet or capsule dosage forms and avoid ﬁrst metabolism which
can be advantageous (Jeong et al., 2008; Hirani et al., 2009; Nagar
et al., 2011; Sharma et al., 2012). For these reasons, over the past
88 A. Solaiman et al. / International Journal of Pharmaceutics 501 (2016) 87–95three decades FDTs have gained considerable attention (Abay and
Ugurlu, 2015) and have been the favourite development of product
development scientists for facilitating ease of medication (Nagar
et al., 2011).
Despite the popularity of FDTs, their formulation can some-
times be challenging. FDTs are made of very porous and soft
moulded matrices or compressed into a tablet with very low
compression force (Deshmukh, 2012) this will allow for fast
disintegration of tablets, however could lead to poor mechanical
properties. Therefore, many FDTs are fragile and will break during
packing, transport or handling by patients. Many technologies have
been used to prepare FDTs, and can be classiﬁed into conventional
technologies such as freeze drying, tablet molding, direct
compression, spray drying and sublimation, or patented technolo-
gies (e.g. Zydis, Quicksolv, Flashtab, Orasolv, Wow tab) (Siddiqui
et al., 2010). The resultant FDT depends on the technology being
used and could therefore have varying properties (Nagar et al.,
2011). Some of the patented technologies have disadvantages. For
example, Zydis technology (Katou et al., 1993), produced by
lypholizing or freeze drying is very light weight and fragile, and
must be dispensed in a special blister pack. Similarly Orasolv
technology (Wehling et al., 1991) have poor mechanical strength
because they are only lightly compressed (Nandy et al., 2011).
Other problems that are related to FDTs include hygroscopicity,
aqueous solubility, tablet size and drug content (Sharma et al.,
2012).
Great efforts have been used to enhance properties of FDTs and
adapt the conventional tableting formulation or the process used
(Pabari and Ramtoola, 2012) in order to compromise between the
two parameters mechanical strength and disintegration time.
Kuno et al. (2005) evaluated rapidly disintegrating tablets
manufactured by phase transition of sugar alcohols. However,
they reported a 4 times increase in tablet hardness and an increase
in disintegration time after heating and increasing sugar alcohol
content. Late and Banga (2009) reported that moisture treatment
of FDTs at 85 and 95% increased tablet hardness; however at the
same time negatively affected the disintegration time. Zhang et al.
(2013) used Eudagrit E-100 to mask the bitter taste of FDT Chinese
herbal medicine and found that the hardness of the tablets
increased with the increased ratio of Eudragit E-100/drug.
However, this lead to a slight increase in disintegration time.
Direct compression represents the simplest and most cost
effective tablet manufacturing technique (Arora and Sethi, 2013).
The basic principle involves the addition of disintegrants and/or
water soluble excipients and/or effervescent agents (Wagh et al.,
2010). The choice and role of excipients are important in the
formulation of FDTs (Nagar et al., 2011). The addition of super-
disintegrants to the formulation plays a major role in the
dissolution and disintegration of the tablets, they provide rapid
disintegration due to the combined effect of swelling and water
absorption by the formulation (Sharma et al., 2012). Super-
disintegrants addition technique for preparing FDTs by direct
compression has been studied by many researchers and found to
be a useful method to provide rapid disintegration (Sharma and
Gupta, 2008; Avani et al., 2008; Jain and Naruka, 2009; Bhardwaj
et al., 2010; Venkata et al., 2012).
Although the FDTs area has passed its infancy there are still
many aspects to improve in the FDTs formulation. The aim of this
study was to enhance the properties of FDTs produced by direct
compression (using Disintequick MCC-25 in combination with
mannitol which is fast dissolving) according to a general multilevel
factorial design to not only have sufﬁcient hardness to withstand
manual handling, but also to have a rapid disintegration time. A
progressive two-stage approach was used in this study. Each stage
involved the change in the ratio of excipients (Mannitol:Filler) and
concentration of superdisintegrant. All FDTs were tested fordifferent parameters such as diameter, hardness, thickness,
friability and disintegration time. The identiﬁcation of interaction
between factors, reduction in number of experiments and factual
modelling of the data, made general multilevel factorial design a
very suitable tool for process optimisation of FDTs.
2. Materials and methods
2.1. Materials
All the excipients used to prepare the tablets were of analytical
grade and consisted of: D-Mannitol (EC-200-711-8, WGK-2,
Sigma–Aldrich, France) used as a diluent; co-processed lactose/
microcrystalline cellulose (MCC) (Distintequik MCC-25, Foremost
Farms, USA) as a ﬁller; croscarmellose sodium (CCNa) (CHP
Carbohydrate Pirna GmbH + Co., KG, Germany) as a superdisinte-
grant and magnesium stearate (Pittsburgh, PA, USA) as lubricant.
2.2. Experimental design and validation
A factorial experiment provides a formula for setting up an
experiment to test the effects of different factors at the same time
(Carter, 1990). General multilevel factorial design was applied
using the statistical software MAT LAB (7.12.0, R2011a) to
optimise and evaluate main effects, interaction effects and
quadratic effects of each factor (X) on the considered response
(Y). This design was selected because it has a certain level of
ﬂexibility in choosing the number of levels for each assigned
factor. It can be used when the equality of levels may consist
constraints towards obtaining more accurate predictable mathe-
matical models. A multilevel factorial design allows for the
calculation of coefﬁcients of a second order model (Kuentz and
Röthlisberger, 2002) which is developed based on the regression
analysis of the statistically signiﬁcant variables. The formulation
ingredients were the studied independent factors, and included %
ﬁller to mannitol (X1) and disintegrant concentration (X2). The
dependent variables (responses) were hardness (Y1), tensile
strength (Y2) and disintegration time (Y3). For X1, seven levels
were assigned as follows; 0, 20, 33.34, 50, 66.67, 80 and 100% w/w,
whereas X2 was assigned ﬁve levels; 1, 3, 5, 7 and 10% w/w.
Therefore, the total prepared formulations were 35. The collected
data was randomly split into two parts. The larger part
(25 samples) was used for calibration of the polynomial models
and the smaller one (10 samples) was used for validation of the
built models. The following second order polynomial equation
(Eq. (1)) was applied as a tool of mathematical modelling (Lewis
et al., 1999)
Y = b0 + b1 X1 + b2 X2 + b12X1 X2 + b11X1 2 + b22X2 2 (1)
where Y is the dependent variable, b0 is the arithmetic mean
response of the seven runs, and b1 and b2 are the estimated
coefﬁcients of the factors X1 and X2. The main effects X1 and X2
represent the average results of changing one factor at a time from
its low to high value.
Three polynomial models were produced and evaluated by
plotting the residuals for both data sets (calibration and validation)
versus the samples, the predicted responses, the frequency and the
probability (not shown). The residuals from a ﬁtted model can be
deﬁned as the differences between the observed (true) and
predicted responses (Yobs–Ypred) (Armstrong, 2006). At each stage,
the calculated multiple correlation coefﬁcient (R2) was shown as
an indicator for the model accuracy. Finally, response surface 3D
plots and contour plots were generated to allow for graphical
illustration of the relationship between the different experimental
variables and the responses (Lundstedt et al., 1998).
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Croscarmellose sodium (CCNa) was chosen as the super-
disintegrant due to its high swelling capacity and effectiveness
at low concentrations. Swells 4–8 folds in less than 10 s (Bala et al.,
2012). Mannitol was chosen as a diluent. However, it could also be
regarded as a sweetening agent. It has many physicochemical
properties such as its sweet taste, cooling sensation that it leaves in
the mouth, hygroscopicity and compactibility (Ohrem et al., 2014).
It has also been shown that the use of mannitol in FDTs reduces
disintegration time (Mizumoto et al., 2005; Chandraskhar et al.,
2009). Disintequick MCC-25 was chosen as the ﬁller, and is made
up of MCC and a-lactose monohydrate. This is a co-processed
excipient designed for direct tableting operations where fast
disintegration is required. The properties of the two excipients
MCC and lactose monohydrate complement each other, and permit
the tablets to be made without granulation (Kerry Group, 2015).
Microcrystalline cellulose which makes up 25% of the chosen ﬁller
is one of the preferred direct compression binders due to its
excellent compactability at low pressures, it is also known to be
self-disintegrating (Jivraj et al., 2000; Thoorens et al., 2014).
Lactose monohydrate which makes up 75% w/w of the chosen ﬁller,
is known to be one of the most common ﬁllers used in tablets, it
also has good compactibility properties, has pleasant taste, and is
non-hygroscopic (Alderborn, 2013). In a study conducted by
Michoel et al. (2002) It was found that co-processed spray driedTable 1
Composition of the prepared fast disintegrating tablets (FDTs).
Formulation
Code
%Filler:
Mannitol
Concentration of
disintegrant (% w/w)
Amount of
Mannitol (mg)
Amoun
Filler (m
F1 0 1% 294 – 
F2 20 235.2 58.8 
F3 33.33 196 98 
F4 50 147 147 
F5 66.67 98 196 
F6 80 58.8 235.2 
F7 100 – 294 
F1 0 3% 288 – 
F2 20 230.4 57.6 
F3 33.33 192 96 
F4 50 144 144 
F5 66.67 96 192 
F6 80 57.6 230.4 
F7 100 – 288 
F1 0 5% 282 – 
F2 20 225.6 56.4 
F3 33.33 188 94 
F4 50 141 141 
F5 66.67 94 188 
F6 80 56.4 225.6 
F7 100 – 282 
F1 0 7% 276 – 
F2 20 220.8 55.2 
F3 33.33 184 92 
F4 50 138 138 
F5 66.67 92 184 
F6 80 55.2 220.8 
F7 100 – 276 
F1 0 10% 267 – 
F2 20 214 53 
F3 33.33 178 89 
F4 50 134 134 
F5 66.67 89 178 
F6 80 53 214 
F7 100 – 267 Microlec 100 composed of 25% w/w microcrystalline cellulose and
75% w/w a—lactose monohydrate showed superior ﬂowability and
binding properties compared to physical mixtures of MCC with
different lactose grades. Consequently, the combination of CCNa,
mannitol and Disintequick MCC-25 complement one another and
impart the desired ﬂowability, compressibility, good mouth feel,
and rapid disintegration.
2.4. Formulation of fast disintegrating tablets (FDTs)
FDTs were prepared by direct compression. The formulation
(Table 1) consisted of 5 different disintegrant (CCNa) concen-
trations (1%, 3%, 5%, 7% and 10% w/w). For each concentration seven
batches with varying ratios of diluent (D-Mannitol): Filler
(Disintequik MCC-25) were used: (1:0), (1:0.25), (1:0.50), (1:1),
(0.50:1), (0.25:1), (0:1) w/w, these were expressed as a percentage
(% ﬁller to mannitol, Table 1) for ease in data manipulation and
interpretation (0, 20, 33.33, 50, 66.67, 80 and 100% w/w). The
concentration of lubricant (magnesium stearate) stayed the same
in all formulations as 1% (w/w). Tablet excipients were weighed
individually on a digital weighing balance (PJ Precisa junior,
400C-3000D, Swis quality, Switzerland) and mixed together in a
turbular mixer (WAB Turbula, system Schatz, Willy A. Bacheofen
machine, AG Maschinenfabrik, Glen Creston Ltd., Switzerland) for
10 min at a speed of 20 rpm. Tablets were then compressed at a
maintained compression force of 24 psig using a single puncht of
g)
Amount of 1%
Disintegrant (mg)
Amount of Lubricant Mg.
stearate (mg) 1%
Total tablet weight
(mg)
3 3 300
3 3 300
3 3 300
3 3 300
3 3 300
3 3 300
3 3 300
9 3 300
9 3 300
9 3 300
9 3 300
9 3 300
9 3 300
9 3 300
15 3 300
15 3 300
15 3 300
15 3 300
15 3 300
15 3 300
15 3 300
21 3 300
21 3 300
21 3 300
21 3 300
21 3 300
21 3 300
21 3 300
30 3 300
30 3 300
30 3 300
30 3 300
30 3 300
30 3 300
30 3 300
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Each batch produced consisted of 40 tablets which were ﬂat faced
and compressed with a target weight of approximately 300 mg.
2.5. Characterisation of FDTs
The formulated FDTs were evaluated for various parameters:
diameter, thickness, uniformity of weight, hardness, tensile
strength, friability and disintegration time.
2.5.1. Determination of tablet diameter and thickness
The diameter (mm) and thickness (mm) of the tablets were
measured using a micrometer screw gauge (Moore and Wright,
Shefﬁeld, England) by placing the tablet between two faces (the
spindle and anvil face), then turning the ratchet until the sample
was trapped between the two faces. Six tablets were taken at
random from each formulation (F1–F7) and the results were
calculated as the mean and standard deviation.
2.5.2. Uniformity of weight
Twenty tablets from each batch were selected at random and
weighed individually on a digital weighing balance (PJ Precisa
Junior, Swis quality, Switzerland). The average weight of the tablets
was then calculated. Percentage deviation of each individual tablet
from the average weight was determined.
2.5.3. Mechanical strength
Crushing strength and friability are two important parameters
for determining the mechanical strength of tablets (Nagar et al.,
2011). The hardness/crushing strength measured in kg/cm2 of six
tablets taken at random from each batch was determined using a
Hardness Tester (SCHIEUNIGE-2E, Model 2E/205, Switzerland). The
average hardness  standard deviation was calculated. The tensile
strength, T, for crushing (MPa) was measured using equation
(Eq. (2)).
T ¼ 2F=p  d  t ð2Þ
where F is the crushing load (N), d, the diameter (m) and t, the
thickness (m).
2.5.4. Friability test
Friability test was performed on 10 randomly selected tablets
using a pre-calibrated friability tester (Model: FRV1000, CopleyFig 1. Disintegration time (seconds) of all FDT formulations F1–F7 at varying disinscientiﬁc LTD. Nottingham, England). The drum was rotated at
25 rpm for 4 min. The tablets were weighed before and after using
the tester and percentage friability was calculated using equation
(Eq. (3)) (British Pharmacopoeia, 2013).
%Friability ¼ w1  w2
w1
 100 ð3Þ
where w1 = Initial weight before test, w2 = ﬁnal weight after test.
2.5.5. Disintegration test
This method was done following the procedure outlined in the
British Pharmacopoeia (2013). Six tablets were separately placed
into a disintegration test apparatus (Type: NE4-COP, Supplied by
Copley scientiﬁc, Nottingham, United Kingdom). The basket rack
assembly of the apparatus was immersed into 800 ml distilled
water maintained at 37  2 C. The time (seconds, s) was recorded
when the tablet had fully disintegrated and no residue was
remaining. The results were recorded as the mean  standard
deviation.
2.6. Statistical analysis
Results obtained from the experiments were expressed as a
mean  standard deviation using Microsoft Excel software (Red-
mond, WA, USA). Statistical experimental design, evaluation of the
models quality of ﬁt and analysis of the data, including calculation
of the constants and regression coefﬁcients was conducted using
the statistical software MAT LAB (7.12.0, R2011a) MathWorks, USA.
3. Results and discussion
The results obtained from characterisation of tablets are
summarised in Tables 2 and 3 and Fig. 1. All FDT formulations
showed acceptable uniformity of weight (Table 2) since they
complied with the British Pharmacopeia standards (2013). Which
states that for an average tablet weight of 250 mg or more, not
more than two tablets should differ from the mean by more than
5%. When preparing directly compressed tablets, the compression
mix has to ﬂow to ensure consistent tablet weight (Thoorens et al.,
2014). Slight variation seen in tablet weight could be attributed to
differences in bulk density of the formulation (Late et al., 2009).
Another reason could be due to the presence of high concen-
trations of mannitol in some of the formulations (F1–F3).tegrant concentrations (1–10%); for formulation composition refer to Table 1.
Table 2
Characteristics of fast disintegrating tablets (weight, thickness and diameter), weight (n = 20), thickness and diameter (n = 6).
Formulation Codea 1% 3% 5% 7% 10%
Weight (mg)
F1 247.2  13.92 253.2  25.02 301.4  27.50 274.5  17.1 285.1  23.2
F2 255.5  15.43 280.2  16.83 305.3  17.10 291.8  17.5 269.2  26.0
F3 279.7  23.69 304.7  16.41 304.7  9.14 300.9  12.0 294.5  13.5
F4 308.7  5.98 307.3  9.39 304.5  8.20 297.4  9.6 308.5  14.4
F5 305.9  5.93 314.6  16.18 300.8  6.66 303.4  11.1 307.3  10.8
F6 302.9  6.03 316.1  9.97 294.5  12.06 301.1  16.7 307.5  14.4
F7 305.1  6.82 322.5  12.96 291.6  12.36 308.1  9.1 305.4  14.0
Thickness (mm)
F1 2.73  0.221 2.96  0.202 3.35  0.189 3.16  0.13 3.14  0.18
F2 2.82  0.352 3.10  0.346 3.33  0.188 3.21  0.18 3.08  0.27
F3 2.95  0.081 3.09  0.017 3.19  0.171 3.11  0.14 3.11  0.19
F4 2.96  0.055 3.02  0.054 3.30  0.202 3.32  0.22 3.03  0.06
F5 2.95  0.041 3.24  0.225 3.48  0.014 3.09  0.17 3.36  0.18
F6 3.43  0.016 3.39  0.176 3.27  0.188 3.27  0.20 3.20  0.28
F7 3.33  0.228 3.12  0.289 3.24  0.292 3.19  0.26 3.22  0.27
Diameter (mm)
F1 9.57  0.008 9.57  0.004 9.59  0.004 9.58  0.00 9.58  0.01
F2 9.57  0.017 9.58  0.005 9.59  0.004 9.58  0.00 9.59  0.01
F3 9.59  0.005 9.58  0.004 9.59  0.008 9.58  0.01 9.58  0.00
F4 9.58  0.008 9.58  0.006 9.58  0.006 9.58  0.00 9.59  0.01
F5 9.58  0.005 9.57  0.000 9.58  0.004 9.57  0.00 9.59  0.00
F6 9.58  0.005 9.58  0.004 9.58  0.000 9.57  0.00 9.58  0.00
F7 9.57  0.004 9.58  0.005 9.57  0.000 9.56  0.00 9.57  0.00
a Refer to Table 1 for formulation composition.
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formulations as hindering the free ﬂow into the tablet dies.
Tablet diameter showed very low variability, tablet thickness
also showed low variability (Table 2) in most of the formulations,
this supports the reproducibility of the formulation and tableting
process used for this study. Tablets’ diameter and thickness results
were used for calculating tablets’ tensile strength.
3.1. General multilevel factorial design—statistical analysis and
mathematical modelling
The data presented (Table 3 and Fig. 1) summarise the
responses for Y1 (hardness), Y2 (tensile strength) and Y3Table 3
Characteristics of fast disintegrating tablets (mechanical strength and friability).
Formulation Codea 1% 3% 
Hardness (N)
F1 38.71  4.33 16.76  4.26 
F2 67.86  8.09 60.76  13.63 
F3 93.92  2.27 89.67  4.75 
F4 132.46  8.35 110.58  4.27 
F5 177.87  7.78 174.77  11.03 
F6 198.39  0.00 193.39  3.26 
F7 379.36  0.00 164.23  21.99 
Tensile Strength (MPa)
F1 0.95  0.124 0.38  0.094 
F2 1.61  0.128 1.32  0.351 
F3 2.11  0.086 1.93  0.099 
F4 2.97  0.196 2.44  0.074 
F5 4.01  0.147 3.61  0.406 
F6 3.84  0.018 3.81  0.245 
F7 4.82  0.369 4.90  0.398 
Friability (%)
F1 16.91 39.562 
F2 13.09 3.845 
F3 0.987 0.970 
F4 6.483 6.481 
F5 0.328 0.444 
F6 0.198 0.257 
F7 0.097 0.030 
Hardness and tensile strength (n = 6), friability (n = 10).
a Refer to Table 1 for formulation composition.(disintegration time) of FDTs. These values were analysed using
statistical software MAT LAB. The polynomial relationships
generated for each response variable using multiple regression
analysis are expressed in Eqs. (4)–(6). The model of best ﬁt was
determined by comparing the statistical parameters correlation
coefﬁcient (R2) and the probability value (P). Results of model
summary statistics are presented in Table 4.
Y1 (Hardness, N) = 86.2473  0.8024  X19.2657  X2+ 0.1566 
X1 X2 + 0.0263  X12 + 0.1741  X22 (4)
Y2 (Tensile Strength, MPa) = 0.7869 + 0.0412  X10.0515  X2 (5)5% 7% 10%
38.87  8.89 42.47  5.60 35.61  6.46
66.56  3.79 55.45  8.02 53.87  6.61
88.85  6.67 73.86  5.04 72.68  4.04
122.01  6.06 96.53  4.00 95.55  8.54
165.95  4.71 137.69  5.57 150.27  9.14
192.41  4.67 161.86  18.11 184.08  7.45
380.32 0.00 415.85 0.00 254.31  0.00
0.77  0.177 0.90  0.15 0.75  0.13
1.33  0.129 1.15  0.12 1.17  0.21
1.86  0.190 1.58  0.07 1.56  0.11
2.47  0.222 1.94  0.19 2.09  0.17
3.17  0.082 2.97  0.19 2.98  0.29
3.92  0.233 3.31  0.50 3.85  0.32
4.71  0.451 3.88  0.32 5.29  0.44
15.979 11.59 12.35
2.217 3.18 2.74
10.836 1.44 1.15
5.652 7.33 8.41
0.433 0.46 0.49
3.051 0.30 0.41
0.101 0.00 0.19
Table 4
Model summary statistics.
Responses (Y) R2 Predicted R2 P
Hardness (Y1) 0.8413 0.8350 <0.0001
Tensile Strength (Y2) 0.9457 0.9611 <0.0001
Disintegration Time (Y3) 0.9054 0.9592 <0.0001
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X2 + 0.0445  X12 + 9.1552X22 (6)
The polynomial equations (Eqs. (4)–(6)) above indicate the
effect of independent factors% ﬁller to mannitol (X1), disintegrant
concentration (X2) and their interactions on the responses Y1, Y2
and Y3. Coefﬁcients containing both factors (e.g. X1X2) shows the
changes in response when two factors are simultaneously changed
(Pathan et al., 2013), while factors at higher order (Xn2) represents
the quadratic relationships (i.e. non-linearity) (Pabari and Ram-
toola, 2012; Zhang et al., 2013).
It can be observed that R2 is reasonably high for all responses
(Table 4), this indicates a high degree of correlation between the
experimental and predicted responses. The R2 of 0.8413 for
hardness indicates that over 84.13% of the variation in the response
is accounted for in the regression equation, similarly over 94.57%
for tensile strength and over 90.54% for disintegration time. Only
statistically signiﬁcant coefﬁcients (P < 0.05) were kept in the
equation. Analysis of variance (ANOVA) of the responses demon-
strates that the quadratic model was signiﬁcant (P < 0.0001) and
valid for each of the responses.
The sign and magnitude of the main effects signify the relative
inﬂuence of each factor on the response (Dhiman and Singh, 2012).
The data clearly indicates that the dependent variables hardness,
tensile strength and DT are strongly dependent on the selected
independent variables (X1 and X2). In Eqs. (5) and (6), the positive
regression coefﬁcient of variable X1 suggests, as would be
expected, an increase in tensile strength and disintegration time
with an increase in% ﬁller to mannitol. However, the negative
regression coefﬁcient seen for independent factor (X2) in Eqs. (4)–
(6) indicates a decrease in hardness, tensile strength and
disintegration time with an increase in disintegrant concentration.
The interaction of % ﬁller to mannitol (X1) and disintegrant
concentration (X2) had a desirable positive impact on hardness (i.e.
causing an increase in hardness), on the other hand they had a
desirable negative impact on disintegration time (i.e. reducing DT).Fig. 2. Response surface (A) and Contour plot (B) showing the effect of% ﬁlle3.2. Analysis of data
The 3—dimensional response surface plots and contour plots for
the effect of% ﬁller to mannitol (X1) and disintegrant concentration
(X2) on FDT hardness (Y1), tensile strength (Y2) and disintegration
time (Y3) are shown in Figs. 2–4. Response surface plots allow for
visual observation of the signiﬁcance of regression equations by
graphically depicting maxima and minima (Late and Banga, 2010).
The variation in values is demonstrated by different colour regions.
3.2.1. Hardness of tablets (Y1)
The hardness of a tablet is an indication of its strength, it is
deﬁned as the force applied across its diameter in order to break
the tablet. Tablets should be able to resist chipping, abrasion or
breaking under conditions of storage, transformation or handling
(Saroha et al., 2013; Nagar et al., 2011) but they should also have no
problem in disintegrating or dissolving (Lee, 2008). Generally, from
the results it was evident that the hardness of all tablets appeared
higher in the presence of larger concentrations of the ﬁller. From
the response surface plot (Fig. 2) it was found that an increase in X1
(% ﬁller to mannitol) from 0% to 20% lead to a sharp increase in Y1
(hardness) from 38.71 N to 67.78 N at low level of disintegrant
concentration (X2). Increasing X1 further to 100% lead to a further
increase in hardness to 379.36 N (9.8 fold increase). At higher
concentrations of X2 (10%) the trend seen was similar showing a
sharp increase (7.1 fold) from 35.61 N to 254.31 N as X1 increased
from 0 to 100% w/w.
On the other hand, it was found that an increase in disintegrant
concentration lead to small decreases in hardness. it was found
that an increase in X2 (disintegrant concentration) from 1% to 10%
lead to a slight decrease in Y1 (hardness) from 38.7 N to 35.61 N at
low level of X1 (% ﬁller to mannitol). The results were similar at all
concentrations of X1 showing a small decrease in hardness. At 80%
and 100% of X1 (% ﬁller to mannitol) the results showed a general
very small decrease in hardness from 198.39 N to 184.08 N and
from 379.36 N to 254.31 N with an increase in X2 from 1% to 10%.
In the case of this experiment X1 shows more impact on
hardness of FDTs than X2. The positive effect of X1 was a
determinant factor of Y1; this made it possible to achieve tablets
with adequate mechanical strength under minimum pressure.
Another tablet property related to crushing strength is friability.
The idea behind friability tests is to mimic the kind of forces that
tablets are subjected to during handling between its production
and administration, and to determine the ability of the tablet to
withstand abrasion during those conditions. (Odeniyi et al., 2003;r to mannitol (X1) and disintegrant concentration (X2) on Hardness (Y1).
Fig. 3. Response surface (A) and Contour plot (B) showing the effect of% ﬁller to mannitol (X1) and disintegrant concentration (X2) on tensile strength (Y2).
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ﬁller, lamination or capping was observed. Generally, formulations
containing larger amounts of ﬁller passed the BP limit test where
friability should be <1%. For these tablets there were no signs of
cracking, splitting or breaking. At 1% and 3% w/w disintegrant
concentration both F1 and F2 showed high friable tablets with%
powder loss between 3.8–39.5% (Table 3); at 5% w/w disintegrant,
F2 showed only 2.2% powder loss and at 7% and 10% w/w
disintegrant, F1 with 100% mannitol showed high value of friability
(12%), while the friability values were greatly reduced to about 3%
for F2 (i.e. with 80% mannitol + 20% Distintequik MCC-25) and to
nearly 1% for F3 (i.e. with 66.67% mannitol + 33.33% Distintequik
MCC-25). Microcrystalline cellulose, MCC, is known to improve the
compactibility/tableting, and is one of the preferred direct
compression binders (Carlin, 2008; Thoorens et al., 2014).
Belda and Mielck (1996) found that cellactose, which is a co-
processed compound consisting of 25% cellulose and 75% a-lactose
monohydrate exhibited enhanced crushing strength compared to
powder mixtures of the same concentration. Reimerdes and
Aufmuth (1992) reported that cellactose was found to impart a
signiﬁcant increase in crushing strength of tablets and reduced
disintegration time, when compared with dry blends. It has also
been reported that the good compactibility of tablets containingFig. 4. Response surface (A) and Contour plot (B) showing the effect of% ﬁller to mcellactose could be attributed to the synergetic effect of
consolidation by fragmentation of lactose and plastic deformation
of cellulose (Gohel, 2005; Arida and Al-Tabakha, 2008). This would
explain why formulations with small amounts of co-processed
Distintequik MCC-25 with mannitol FDTs can enhance mechanical
strength properties of tablets whilst keeping fast disintegration
time; those properties are very desirable/demanding for FDTs.
Hence and according to this study, F2 (with 80% mannitol + 20%
Distintequik MCC-25 + 5% w/w croscarmellose sodium) and F3
(with 66.67% mannitol + 33.33% Distintequik MCC-25 + 7% or 10%
w/w croscarmellose sodium) can overcome the issues (for example
processing technique, using blister packs and hygroscopicity) with
the most of existing commercially available FDTs.
3.2.2. Tensile strength of tablets (Y2)
Response surface plot (Fig. 3) described the effects of X1 (% ﬁller
to mannitol), X2 (disintegrant concetration) and their interactions
on Y2 (tensile strength). The observations seen were similar to that
described for hardness. It was found that Y2 (tensile strength) was
strongly effected by X1 (% ﬁller to mannitol), with a sharp increase
in Y2 (tensile strength) from 0.95 MPa to 4.82 MPa as X1 (% ﬁller/
Mannitol) increased from 0% to 20% at low level X2 (disintegrant
concentration). This trend was repeated at higher concentrationsannitol (X1) and disintegrant concentration (X2) on disintegration time (Y3).
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and from 0.75 MPa to 5.29 MPa at 10% X2. The positive effect of X1
as seen in regression equation 3 and response surface plot was a
determinant factor of Y2, this made it possible to achieve tablets
with adequate tensile strength.
The effect of disintegrant concentration on Y2 (tensile strength)
was small, with a small decrease in Y2 from 0.95 M to 0.75 M as X2
(disintegrant concentration) increased from 1% to 10% at low level
of X1 (% ﬁller to mannitol). This pattern was repeated at higher
concentrations of X1. However, at 80% and 100% X1, the decrease in
tensile strength was even smaller and the results were not
systematic in one direction (see also Table 3).
3.2.3. Disintegration time (DT) of tablets (Y3)
Superdisintegrants accelerate disintegration of tablets by virtue
of their ability to absorb a large amount of water when exposed to
an aqueous environment. The combined effect of swelling and
water absorption results in breaking of tablets and therefore faster
disintegration (Sharma et al., 2012; Vimal et al., 2013). Combina-
tions of swelling and/or wicking and/or deformation are the
mechanisms of disintegrant action. The disintegrants have the
ability to oppose the efﬁciency of the tablet binder and the physical
forces that act under compression to form the tablet (Vimal and
Aarathi, 2013). According to the BP (2013), orodisoersible tablets
disintegrate within 3 min. For formualtions F1 and F2, tablets
disintegrated at all disintegrant concentrations in less than 3 min
(Fig. 1). The fastest disintegration time of 23 s being for F1
containing 5% disintegrant and 0% ﬁller to mannitol.77
Response surface plot (Fig. 4) described the effect of X1 (% ﬁller
to mannitol) and X2 (disintegrant concentration) and their
interaction on Y3 (DT). It was found that DT was strongly affected
by X1 and X2.
Response surface plot shows that DT (Y3) was directly
proportional to% ﬁller/mannitol (X1) with a rapid and sharp
increase in DT as X1 increased from 0% to 100% at low disintegrant
concentrations (X2). The trend was repeated at high level of X2with
a sharp increase in Y3 from 40 s to 432 s as X1 increased from 0% to
100%. It is clear from the response surface plot and from Fig. 1. that
the lowest disintegration times were achieved at 5%, 7% and 10%
disintegrant concentrations and in formulations containing none
or only small amounts of ﬁller. The results also show that Y3 was
inversely proportional to X2 showing a sharp decrease in DT from
72 s to 40 s as disintegrant concentration increased from 1% to 10%
at 0% X1 (% ﬁller to mannitol). The trend was repeated with the rise
in X1 showing a sharp decrease in DT from 99 s to 48 s at 20% ﬁller
to mannitol and from 1340 s to 432 at 100% ﬁller to mannitol as
disintegrant concentration increased from 1% to 10%. Therefore it is
clear that DT (Y3) is greater at higher levels of% ﬁller to mannitol
(X2). This observation could be attributed to the increase in
hardness observed (Fig. 2,Table 3) with an increase in% ﬁller to
mannitol. Similar observations were found in a study by Marais
et al. (2003) where the disintegration time of DC furosemide
tablets decreased as the disintegration concentration (croscar-
mellose sodium A) increased above 0.625% w/w. However, an
increase in the crushing strength as a result of increased
compression force prolonged the disintegration time. The in-
creased hardness was thought to lead to reduced penetration of
liquid into the tablet structure hence reducing the disintegrating
force inside the tablet. In this current study, there was a clear
increase in tablet hardness with the increase in% ﬁller to mannitol.
Formulations F1, despite showing very fast disintegration
properties, which is expected as they contain 100% mannitol, they
had poor mechanical properties. Generally, most of tablets
(containing 3–10% disintegrant) in formulations F2 and F3 had
sufﬁcient hardness, hardness values ranged between 53.87–
89.67 N (5.49–9.15 kgf), and at the same time disintegrated atabout or less than 3 min; the tablets with the maximum hardness
i.e. 89.67 N disintegrated within 204 s and was for F3 with 3%
disintegrant and 33.33% ﬁller to mannitol; and the F2 formulation
containing 5% disintegrant and 20% ﬁller to mannitol had a
hardness of 66.56 N (6.79 kgf), a tensile strength of 1.33 MPa and
disintegrated within 30 s (the fastest disintegration time for F2–
F3). Formulations F4–F7 had hardness values ranging between
95.55 N (9.74 kgf) and 415.85 N (42.4 kgf), these formulations as
would be expected produced considerably higher disintegration
times (Fig. 1) and would therefore not be suitable as FDTs.
4. Conclusion
Fast disintegrating tablets have become a rapid growing area in
the pharmaceutical industry. Two of the key parameters for
producing desirable and successful FDTs is rapid disintegration
upon placing in the mouth, and good mechanical strength to
withstand handling, packaging and transport. This study demon-
strated that the FDTs prepared by direct compression, were
successfully optimised by applying general multilevel factorial
design. Disintegrant concentration and% ﬁller to mannitol were
observed to have an interactive effect on the hardness, tensile
strength and disintegration time of the FDTs. The mathematical
models showed a good degree of correlation between experimen-
tal and predicated responses of the optimised formulations. The
optimum formulation regarding DT was found to be for F2 with 5%
disintegrant and 20% ﬁller/mannitol. This formulation gave the
best results with fast disintegration (30 s) and strong mechanical
properties showing a hardness of 66.56 N (6.79 kg/cm2) and tensile
strength of 1.33 MPa. These process parameters may have wider
applications within the pharmaceutical industry, saving both time
and cost of the formulation.
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